Feature | September 21, 2011| Dave Fornell

Costs May Outweigh Returns of Developing Device Innovations

I repeatedly hear two competing, contradictory themes discussed at every symposia – the need to lower healthcare costs and that costs to bring new technology to market are rapidly increasing. The U.S. leadership position as a medical technological innovator is slipping to Europe, where there is a much wider selection of devices to choose from. The requirements to gain CE mark clearance are much more lenient than U.S. Food and Drug Administration (FDA) pre-market approval.  


Of the many devices available in Europe, only a fraction of the vendors that created them will seek FDA approval, because it simply costs too much to bring a product to market. Most cardiac devices take tens of millions of dollars to develop, bench-test and then go through years of clinical trials. FDA recognizes the increasing cost has resulted in a decreased number of new drug and device submissions. This translates into fewer medical advances reaching the U.S. market.


“Our challenge is to be frugal while improving healthcare…but we will not have new medical devices if we continue on the path we are currently on,” said Michell Frucoff, M.D., FACC, Duke University, during a presentation on device innovation at the American College of Cardiology (ACC) 2011. “Even though we are the second largest market for these medical devices, we are the last to gain access to these devices.”


There is an increasing call from physicians and vendors for closer collaboration in trials between European, FDA and Japanese regulators.  Currently, all three review systems are disparate, impeding efficiency and adding costs to bring innovations to market. Frucoff explained CE mark review takes one to two years, FDA an additional three to five years, and an extra three to five years on top of FDA to achieve market approval in Japan.


The FDA does recognize its requirements cause delays and it wants to help spur innovation instead of deterring it, said Bram Zuckerman, M.D., FACC, FDA director of cardiovascular devices, Center for Devices and Radiological Health (CDRH). He said the CDRH developed the Medical Device Innovation Initiative. This encourages early, free consultations with FDA staff prior to an FDA submission to address potential issues that would delay the review process. He said the FDA is currently revising its rules for all types of medical technology review and is attempting to make better use of new statistical trials. The FDA is also starting to coordinate with Japan for a single review and pivotal trial process for devices, rather than two.


In August the FDA released its “Strategic Plan for Regulatory Science,” a sweeping initiative to modernize the tools and methods the agency uses to evaluate safety and effectiveness. (For more, http://www.dicardiology.com/article/fda-wants-modernize-its-regulatory-review-process)


It is hoped these new initiatives will help. If not, hospitals may consider investing in overseas branches and developing medical tourism programs.

Related Content

Sci-image, Scimage, CVIS, CIIMS, Cpacs c-pacs, cardiovascular information system

Today's cardiovascular information systems need to incorporate all facets of the cardiology department, including subspecialties, to allow a complete picture of a patient's record. These data also need to be able to be shared with enterprise data systems, such as the electronic medical record (EMR). This image is from ScImage, illustrating the various aspects that integrate to make up a complete CVIS. 

 

Feature | September 29, 2016 | Val Kapitula, RT(R), PMP, CIIP
Cardiovascular Information and Imaging Systems (CVIS) have existed for many years in the dedicated sub-specialty area
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
News | Cardiac Diagnostics| September 28, 2016
Increasing stomach fat – especially the “hidden fat” in your abdomen – is associated with newly identified and...
Neuravi, EmboTrap II stent retriever, thrombectomy device, acute stroke, European launch, CE Mark
News | Thrombectomy Devices| September 28, 2016
Neuravi recently announced Conformité Européenne (CE) Mark approval and launch of the company’s newly available...
Infinix 4D CT

Toshiba's Infinix 4D CT, which combines CT with angiography in the interventional lab.

Feature | Angiography| September 28, 2016 | Tom Watson BS, RCVT, Clinical Analyst, MD Buyline
One of the more significant advancements for interventional X-ray (IXR) in the past few years has been a significantl
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
Avinger, U.S. Department of Veterans Affairs, VA, Lumivascular technology, FSS Contract Award
News | Optical Coherence Tomography (OCT)| September 27, 2016
Avinger Inc. recently announced the company has received an FSS Contract Award from the U.S. Department of Veterans...
BioTelemetry, CE Mark, Holter analysis software
News | Holter Monitoring Systems| September 27, 2016
BioTelemetry Inc. announced in late August that the company has received CE mark approval of its Holter analysis...
Bard, Lutonix 014 DCB, drug-coated balloon, six-month endpoint, FDA IDE trial
Technology | Drug-Eluting Balloons| September 26, 2016
C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Overlay Init